To report the first case of stage IIIB, ALK-positive lung squamous cell carcinoma (LSCC) achieving complete pathological response to neoadjuvant ensartinib.
Key Findings:
The patient achieved a rapid partial response after 4 weeks of ensartinib.
Complete pathological response was confirmed after surgery with no tumor cells detected.
Mild rash was the only observed toxicity during treatment.
Interpretation:
Limitations:
The study is based on a single case report, limiting generalizability.
Limited data exists regarding the use of ALK inhibitors in the neoadjuvant setting for LSCC.
